Article Text
Letter
Cost minimisation of RSV prevention with palivizumab
Statistics from Altmetric.com
An outpatient respiratory syncytial virus (RSV) prophylaxis programme has been provided in Glasgow since 1999. Initially only high risk neonates were included but subsequently patients with congenital heart disease, congenital lung abnormalities, and other complex histories have been offered prophylaxis. Early attempts to minimise drug wastage via a buddy system were unsuccessful, with only a 1.4% cost saving in 2003–04. During the 2004–05 RSV season we aimed to strictly coordinate the delivery of effective prophylaxis while minimising drug costs through patient cohorting and …
Footnotes
-
Competing interests: none declared